Completed PHASE3 INTERVENTIONAL 2-arm NCT00496652

DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC

DAHANCA 19: A Randomized Study of the Importance of the EGFr-Inhibitor Zalutumumab for the Outcome After Primary Curative Radiotherapy for Squamous Cell Carcinoma of the Head and Neck

Sponsor: Danish Head and Neck Cancer Group

Conditions Cancer of the Head and Neck

Interventions Radiotherapy Zalutumumab

Updated 5 times since 2017 Last updated: Nov 22, 2016 Started: Nov 30, 2007 Primary completion: Jul 31, 2012 Completion: Nov 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00496652, this PHASE3 trial focuses on Cancer of the Head and Neck and remains completed. Sponsored by Danish Head and Neck Cancer Group, it has been updated 5 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Nov 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Danish Head and Neck Cancer Group

Data source: Danish Head and Neck Cancer Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Aarhus, Denmark